Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 06/22 10:02:31 pm
122.84 USD   +1.14%
06/23JOHNSON & JOHNS : Real-World Evidence Shows Oral INVOKANA® (canaglif..
PU
06/22JOHNSON & JOHNS : current report
PU
06/22JOHNSON & JOHNS : Remakes Top Leadership -- Update
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Johnson & Johnson : Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:32pm CEST

Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP Reports

By a News Reporter-Staff News Editor at Women's Health Weekly -- Plaintiffs pursuing talcum powder lawsuits in Missouri state court claim that newly unsealed documents show that Johnson & Johnson has known since the 1970s that its talc-based powders contained asbestos fibers, which could increase the risk of ovarian cancer in women who used the products for daily feminine hygiene. (Case No. 1522-CC10417, Circuit Court, City of St. Louis, Missouri)

"Our Firm is representing women who allegedly developed ovarian cancer due to Johnson & Johnson's talcum powder products. These documents are of great interest to our clients, and we will continue to monitor the Missouri litigation for any other developments that could impact their claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with Johnson & Johnson'sBaby Powder and Shower-to-Shower products (see also Bernstein Liebhard Llp).

Keywords for this news article include: Talc, Asbestos, Oncology, Gynecology, Legal Issues, Silicic Acid, Women's Health, Silicon Dioxide, Silicon Compounds, Inorganic Chemicals, Magnesium Silicates, Risk and Prevention, Mixed Ovarian Cancer, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
06/23JOHNSON & JOHNSON : Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Res..
PU
06/22JOHNSON & JOHNSON : current report
PU
06/22JOHNSON & JOHNSON : Change in Directors or Principal Officers, Regulation FD Dis..
AQ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22JOHNSON & JOHNSON : Announces Retirement of Group Worldwide Chairman, Sandra E. ..
PU
06/22JOHNSON & JOHNSON : Appoints Senior Leaders to Executive Committee
PR
06/22JOHNSON & JOHNSON : Janssen Phase 3 Study Programme of Esketamine Nasal Spray in..
AQ
06/22JOHNSON & JOHNSON : Governor Cuomo Announces Grand Opening of New Life Sciences ..
AQ
06/21JOHNSON & JOHNSON : Innovation Announces Launch of Shanghai Lung Cancer Innovati..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22Johnson & Jobnson chairman to retire 
06/22HP INC. : Buy For Total Return And Gain From Share Buybacks 
06/22The No. 1 Stock In The World (Redux) - Part 3 
06/21Establishment Labs files for initial public offering 
Financials ($)
Sales 2018 81 525 M
EBIT 2018 24 885 M
Net income 2018 16 158 M
Debt 2018 10 673 M
Yield 2018 2,93%
P/E ratio 2018 17,80
P/E ratio 2019 16,42
EV / Sales 2018 4,17x
EV / Sales 2019 3,87x
Capitalization 329 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 144 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373
AMGEN6.47%122 515